On the 21st, Professor Kim Sang-gyun (right) of the Department of Gastroenterology at Seoul National University Hospital and Park Geun-tae, President of the Korean Association of Internal Medicine, are giving lectures at the Mukosta Extended-Release Tablet Launch Online Symposium. (Photo by Boryung Pharmaceutical)
[Asia Economy Reporter Kim Ji-hee] Boryung Pharmaceutical announced on the 22nd that it held an online symposium on the 21st to commemorate the launch of Mucosta Extended-Release Tablets (active ingredient: Rebamipide). This product is characterized by being the only one among products with the same ingredient to have a bilayer tablet structure consisting of an immediate-release layer and an extended-release layer.
The symposium, themed "Optimal Gastrointestinal Disease Treatment Using Mucosta Extended-Release Tablets," was chaired by Park Geun-tae, president of the Korean Association of Internal Medicine, with Professor Kim Sang-gyun of Seoul National University Hospital's Department of Gastroenterology as the speaker. The lecture introduced the safest and most effective treatment methods using Mucosta Extended-Release Tablets for patients with gastrointestinal diseases and discussed future directions for treatment development.
Developed by Otsuka Pharmaceutical Korea and co-marketed with Boryung Pharmaceutical, Mucosta Extended-Release Tablets are an improved formulation of the existing Mucosta in extended-release tablet form. Designed with a bilayer tablet structure where the immediate-release layer and extended-release layer account for 40% and 60% respectively, it provides rapid effect while maintaining prolonged efficacy. This allows the dosing frequency to be reduced to twice daily.
Although Rebamipide has a bitter taste due to its properties, Mucosta Extended-Release Tablets are film-coated like Mucosta, which is expected to improve patient medication adherence.
Yoon Sang-bae, Executive Director of the Rx Division at Boryung Pharmaceutical, said, "Currently, Boryung Pharmaceutical is co-promoting excellent products from Otsuka Pharmaceutical Korea, such as Mucosta and Mucosta Extended-Release Tablets, based on its established position in the gastrointestinal treatment market through products like Stoga. We plan to strengthen our sales and marketing capabilities based on outstanding product quality to increase our market share in the gastrointestinal drug market."
Meanwhile, Otsuka Pharmaceutical Korea and Boryung Pharmaceutical have signed a co-promotion agreement for the peptic ulcer drug 'Mucosta' and the antithrombotic agent 'Pretal,' and have been jointly conducting sales and marketing activities since this month.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
